| Literature DB >> 27091142 |
Stephanie Dellicour1, Jenny Hill2, Jane Bruce3, Peter Ouma4, Doris Marwanga4, Peter Otieno4, Meghna Desai5, Mary J Hamel5, Simon Kariuki4, Jayne Webster3.
Abstract
BACKGROUND: Coverage with malaria in pregnancy interventions remains unacceptably low. Implementation research is needed to identify and quantify the bottlenecks for the delivery and use of these life-saving interventions through antenatal clinics (ANC).Entities:
Keywords: Antenatal care; Insecticide-treated nets; Intermittent preventive treatment; Kenya; Malaria in pregnancy; Predictors; Service delivery; Sub-Saharan Africa; Systems effectiveness
Mesh:
Substances:
Year: 2016 PMID: 27091142 PMCID: PMC4835845 DOI: 10.1186/s12936-016-1261-2
Source DB: PubMed Journal: Malar J ISSN: 1475-2875 Impact factor: 2.979
Fig. 1Kenya guidelines for prevention of malaria in pregnancy (2008 edition) [13]
Fig. 2Intermediate steps in the delivery of IPTp-SP and ITN through antenatal care
Description of the health facilities characteristics
| Type | 1 | 2 | 3 | 4 | 5 | 6 | 7 | 8 | 9 |
|---|---|---|---|---|---|---|---|---|---|
| Sub-district hospital | Sub-district hospital | Dispensary | District hospital | Mission hospital | Health centre | Dispensary | Health centre | Health centre | |
| Level | 4 | 4 | 2 | 4 | 4 | 3 | 2 | 3 | 3 |
| Catchment population | 79,200 | 88,000 | 7500 | 23,400 | 6825 | 13,200 | 8100 | 5808 | 19,800 |
| Number of ANC visits in 2009 | 2734.00 | 1509.00 | 363.00 | 1156.00 | 500.00 | 449.00 | 807.00 | 1354.00 | 1038.00 |
| Staffing | |||||||||
| Medical officer | 1 | 1 | 1 | ||||||
| Clinical officer | 9 | 2 | 1 | 6 | 1 | 1 | 2 | 1 | |
| Pharmacist | 1 | 1 | 1 | ||||||
| Public health/registered nurse | 8 | 8 | 3 | 12 | 6 | 6 | 2 | 3 | |
| Enrolled nurse | 10 | 6 | 6 | 2 | 1 | 2 | 2 | 4 | |
| Assistant nurse | 5 | ||||||||
| Lab technician | 3 | 3 | 2 | 4 | 2 | 2 | |||
| Number of staff usually working in ANC | 4 | 2 | 4 | 4 | 9 | 5 | 3 | 4 | 12 |
| Time to closest referral centre (min) | 45 | 60 | 45 | 30 | 30 | 90 | 60 | 60 | 30 |
| Laboratory | Yes | Yes | Yes | Yes | Yes | Yes | |||
| Pharmacy | Yes | Yes | Yes | Yes | Yes | Yes | Yes | Yes | |
| Number of observation | 222 | 115 | 50 | 99 | 37 | 42 | 64 | 92 | 64 |
| Number of exit interviews | 128 | 115 | 50 | 57 | 37 | 35 | 56 | 86 | 49 |
Characteristics of health workers enrolled in health facilities where ANC observations took place (number (%) unless otherwise specified)
| Health facility | 1 | 2 | 3 | 4 | 5 | 6 | 7 | 8 | 9 | Overall |
|---|---|---|---|---|---|---|---|---|---|---|
| Number of staff interviewed | 16 | 8 | 3 | 16 | 7 | 5 | 2 | 9 | 12 | 78 |
| Number female | 9 (56.3) | 3 (37.5) | 3 (100.0) | 11 (68.8) | 4 (57.1) | 4 (80.0) | 2 (100.0) | 3 (33.3) | 9 (75.0) | 48 (61.5) |
| Mean age in years (SD) | 29 (8) | 34 (8) | 34 (8) | 31 (7) | 34 (11) | 34 (11) | 38 (5) | 37 (11) | 34 (10) | 33 (9) |
| Number resident in the district | 3 (18.8) | 0 (0.0) | 1 (33.3) | 4 (25.0) | 1 (14.3) | 1 (20.0) | 0 (0.0) | 6 (66.7) | 3 (25.0) | 21 (25.6) |
| Number from district | 4 (25.0) | 1 (12.5) | 1 (33.3) | 1 (43.8) | 3 (42.9) | 1 (20.0) | 1 (50.0) | 6 (66.7) | 4 (33.3) | 31 (37.8) |
| Ethnicity | ||||||||||
| Luo | 6 (46.2) | 5 (62.5) | 3 (100.0) | 14 (93.3) | 6 (85.7) | 2 (40.0) | 2 (100.0) | 8 (88.9) | 7 (58.3) | 53 (71.6) |
| Luyha | 4 (30.8) | 0 | 0 | 0 | 0 | 0 | 0 | 1 (11.1) | 2 (16.7) | 7 (9.5) |
| Kalenjin | 1 (7.7) | 2 (25.0) | 0 | 1 (6.7) | 0 | 1 (20.0) | 0 | 0 | 3 (25.0) | 8 (10.8) |
| Kisi | 2 (15.4) | 1 (12.5) | 0 | 0 | 1 (14.3) | 1 (20.0) | 0 | 0 | 0 | 5 (6.8) |
| Other | 0 | 0 | 0 | 0 | 0 | 1 (20.0) | 0 | 0 | 0 | 1 (1.4) |
| Mean years in health facility (SD) | 0 (1) | 2 (3) | 3 (5) | 2 (2) | 3 (3) | 0 (0) | 4 (2) | 7 (7) | 3 (3) | 2 (4) |
| Number working in other departments | 15 (93.8) | 7 (87.5) | 2 (66.7) | 12 (80.0) | 6 (85.7) | 4 (80.0) | 2 (100.0) | 9 (100.0) | 11 (91.7) | 72 (88.9) |
| Highest qualifications | ||||||||||
| Medical or clinical officers | 3 | 2 | 0 | 3 | 1 | 1 | 0 | 0 | 1 | 11 |
| Pharmacist | 1 | 0 | 0 | 1 | 0 | 0 | 0 | 0 | 0 | 2 |
| Registered nurse/midwife | 2 | 2 | 2 | 4 | 4 | 3 | 0 | 0 | 4 | 21 |
| Enrolled nurse/midwife | 1 | 0 | 1 | 0 | 0 | 1 | 0 | 0 | 3 | 6 |
| Nurse aid | 0 | 0 | 0 | 0 | 1 | 0 | 0 | 0 | 0 | 1 |
| Laboratory technician | 1 | 1 | 0 | 2 | 1 | 0 | 0 | 2 | 1 | 8 |
| Student | 6 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 2 | 8 |
| Other | 1 | 1 | 1 | 1 | 0 | 0 | 0 | 5 | 0 | 9 |
| Number with FANC training in last 5 years | 4 (25.0) | 1 (12.5) | 1 (33.3) | 1 (6.25) | 0 (0.0) | 0 (0.0) | 0 (0.0) | 1 (11.1) | 2 (16.7) | 10 (12.2) |
| Number with PMTCT training in last 5 years | 6 (37.5) | 4 (50.0) | 2 (66.7) | 10 (62.5) | 3 (42.9) | 2 (40.0) | 1 (50.0) | 7 (77.8) | 6 (50.0) | 41 (50.0) |
| Number with MiP in training last 5 years | 3 (8.8) | 3 (37.5) | 1 (33.3) | 2 (12.5) | 1 (14.3) | 0 (0.0) | 0 (0.0) | 2 (2.2) | 1 (9.3) | 15 (15.9) |
FANC focused antenatal care, MiP malaria in pregnancy, PMTCT prevention of mother to child transmission of HIV, SD standard deviation
Characteristics of pregnant women (number (%) unless otherwise specified)
| Level 4 | Level 3 | Level 2 | Overall | |
|---|---|---|---|---|
| Number | 473 | 198 | 114 | 785 |
| Mean age (SD) | 23.8 (5.9) | 23.5 (5.6) | 24.7 (6.8) | 23.9 (6.0) |
| Age group | ||||
| <15 years | 4 (0.9) | 3 (1.5) | 2 (1.8) | 9 (1.2) |
| 15–20 years | 117 (24.7) | 48 (24.2) | 28 (24.6) | 193 (24.6) |
| 20–29 years | 269 (56.9) | 114 (57.6) | 57 (50.0) | 440 (56.1) |
| 30–39 years | 75 (15.9) | 30 (15.2) | 22 (19.3) | 127 (16.2) |
| 40–49 years | 8 (1.69) | 1 (0.5) | 4 (3.5) | 13 (1.7) |
| ≥50 years | 0 (0.0) | 2 (1.0) | 1 (0.9) | 3 (0.4) |
| Marital status | ||||
| Single | 77 (16.5) | 40 (20.2) | 17 (15.0) | 134 (17.3) |
| Married | 384 (82.4) | 154 (77.8) | 92 (81.4) | 630 (81.2) |
| Divorced | 2 (0.4) | 3 (1.5) | 4 (3.5) | 9 (1.2) |
| Widowed | 3 (0.6) | 1 (0.5) | 0 (0.0) | 4 (0.5) |
| Highest level of education | ||||
| None | 144 (30.4) | 84 (42.4) | 70 (61.4) | 298 (38.0) |
| Primary | 271 (57.3) | 99 (50.0) | 38 (33.3) | 408 (52.0) |
| Secondary | 41 (8.7) | 11 (5.6) | 5 (4.4) | 57 (7.3) |
| Higher education | 17 (3.6) | 4 (2.0) | 1 (0.9) | 22 (2.8) |
| Gravidity | ||||
| Primi | 145 (30.7) | 71 (35.9) | 27 (23.7) | 243 (31.0) |
| 2–3 | 272 (57.5) | 101 (51.0) | 56 (49.1) | 429 (54.7) |
| 4+ | 56 (11.8) | 26 (13.1) | 31 (27.2) | 113 (14.4) |
| Number of children under 5 | ||||
| 0 | 209 (44.6) | 85 (43.2) | 35 (31.5) | 329 (42.3) |
| 1 | 141 (30.1) | 65 (33.0) | 37 (33.3) | 243 (31.3) |
| 2–4 | 117 (25.0) | 45 (22.8) | 39 (35.1) | 201 (25.9) |
| 5+ | 2 (0.4) | 2 (1.0) | 0 (0.0) | 4 (0.5) |
| Socioeconomic status group | ||||
| Poorest | 44 (13.1) | 28 (16.5) | 51 (48.1) | 123 (20.1) |
| Very poor | 54 (16.0) | 50 (29.4) | 19 (17.9) | 123 (20.1) |
| Poor | 63 (18.7) | 45 (26.5) | 14 (13.2) | 122 (19.9) |
| Less poor | 79 (23.4) | 29 (17.1) | 15 (14.2) | 123 (20.1) |
| Least poor | 97 (28.8) | 18 (10.6) | 7 (6.6) | 122 (19.9) |
|
|
|
|
|
|
| Gestation trimester | ||||
| First | 12 (2.5) | 5 (2.5) | 3 (2.6) | 20 (2.6) |
| 2nd | 155 (32.8) | 68 (34.3) | 36 (31.6) | 259 (33.0) |
| 3rd | 228 (48.2) | 98 (49.5) | 67 (58.8) | 393 (50.1) |
|
|
|
|
|
|
| ANC visit number | ||||
| 1 | 190 (40.2) | 111 (55.8) | 43 (37.4) | 344 (43.7) |
| 2 | 117 (24.7) | 35 (17.6) | 32 (27.8) | 184 (23.4) |
| 3 | 82 (17.3) | 22 (11.1) | 19 (16.5) | 123 (15.6) |
| 4 | 32 (6.8) | 8 (4.0) | 12 (10.4) | 52 (6.6) |
| 5 | 6 (1.3) | 2 (1.0) | 0 (0.0) | 8 (1.0) |
| 6 | 3 (0.6) | 2 (1.0) | 0 (0.0) | 5 (0.6) |
|
|
|
|
|
|
| Reason for visit | ||||
| Routine ANC | 325 (95.9) | 162 (95.3) | 102 (96.2) | 587 (95.8) |
| Routine ANC + ill | 2 (0.6) | 3 (1.8) | 1 (0.9) | 6 (1.0) |
| Ill | 10 (3.0) | 4 (2.4) | 3 (2.8) | 17 (2.8) |
|
|
|
|
|
|
aInformation on assets was only collected for participants completing exit interviews
ANC antenatal care; SD standard deviation
Intermediate and cumulative system effectiveness for the delivery of IPTp with and without directly observed therapy (DOT) through the antenatal care platform
| Level 4 | Levels 3 and 2 | |||||
|---|---|---|---|---|---|---|
| n | Intermediate | Cumulative | n | Intermediate | Cumulative | |
| % (95 % CI) | % (95 % CI) | % (95 % CI) | % (95 % CI) | |||
| With DOT | ||||||
| IPTp eligiblea | 304 | 242 | ||||
| SP in stock | 304 | 100.0 | 100.0 | 242 | 100.0 | 100.0 |
| Receive SP during visit | 208 |
| 68.6 [60.2, 75.9] | 198 | 80.3 [61.7, 91.1] | 80.3 [61.7, 91.1] |
| Receive three doses SP during visit | 206 | 99.0 [96.1, 99.7] | 67.8 [60.6, 74.3] | 187 | 94.1 [77.5, 98.7] | 75.5 [55.4, 88.5] |
| Took SP by DOT | 121 |
| 39.8 [12.5, 75.4] | 129 |
| 53.3 [21.0, 83.1] |
| With or without DOTb | ||||||
| IPTp eligiblea | 208 | 220 | ||||
| SP in stock | 208 | 100.0 | 100.0 | 220 | 100.0 | 100.0 |
| Being given SP during visit | 140 |
| 67.5 [60.3, 74.0] | 181 | 79.7 [60.8, 90.9] | 79.7 [60.8, 90.9] |
| Being given three doses SP during visit | 139 | 99.2 [96.2, 99.9] | 67.0 [60.6, 72.8] | 170 | 93.4 [74.5, 98.6] | 74.5 [53.6, 88.1] |
| Has SP on exit | 52 | 88.0 [63.3, 96.9] | 40.3 [18.2, 67.2] | 50 | 93.4 [45.9, 99.6] | 54.0 [17.6, 86.5] |
| Knows to take three tablets SP | 48 | 92.1 [78.1, 97.5] | 37.2 [17.7, 61.9] | 49 | 96.4 [59.6, 99.8] | 52.5 [16.3, 86.2] |
| SP by DOT | 80 |
| 39.1 [15.9, 68.6] | 118 |
| 52.9 [20.2, 83.2] |
| Knows to take three tablets SP or took SP as DOT | 128 | 92.1 [87.4, 95.1] | 61.7 [55.7, 67.4] | 167 | 97.1 [70.6, 99.8] | 72.3 [46.9, 88.6] |
aIPTp eligibility according to Kenya national guidelines was women not taking cotrimoxazole (or being HIV positive as a proxy for cotrimoxazole use), having felt the baby move (i.e. past quickening) or being 16 weeks gestation or over
bAnalysis limited to participants completing exit interviews where information on availability of SP at exit was collected
ANC antenatal care; CI confidence interval, DOT directly observed therapy, IPTp intermittent preventive treatment SP sulfadoxine–pyrimethamine
Fig. 3a Cumulative system effectiveness for the delivery of IPTp-SP by DOT through ANC and b Cumulative system effectiveness for the delivery of IPTp-SP through ANC either by DOT or pregnant women having three tablets of SP at exit and knowing how to take them. Intermediate steps are as follows: step 1, Eligible pregnant women attend ANC in her second trimester; step 2, SP is in stock; step 3, SP is given to the pregnant women; step 4, the correct dose of SP is given (three tablets); step 5, the pregnant women take IPTp-SP by DOT (a) or either by DOT or pregnant women having three tablets of SP at exit and knowing how to take them (b)
Intermediate and cumulative system effectiveness for the delivery of ITN at first antenatal care visit
| Steps for ITN delivery | Level 4 | Levels 3 and 2 | ||||
|---|---|---|---|---|---|---|
| n | Intermediate | Cumulative | n | Intermediate | Cumulative | |
| % (95 % CI) | % (95 % CI) | % (95 % CI) | % (95 % CI) | |||
| Attend ANC | 142 | 100.0 | 135 | 100.0 | ||
| ITN in stock | 127 | 90.0 [76.9, 96.1] | 90.0 [76.9, 96.1] | 115 | 82.6 [47.6, 96.1] | 82.6 [47.6, 96.1] |
| Given ITN during consultation by healthcare provider | 91 |
| 63.1 [55.9, 69.7] | 94 | 83.0 [61.2, 93.8] | 68.6 [38.0, 88.6] |
| Women took ITN | 91 | 100 | 63.1 [55.9, 69.7] | 93 | 98.4 [81.8, 99.9] | 67.4 [35.6, 88.6] |
ANC antenatal care, CI confidence interval, ITN, insecticide-treated net
Fig. 4Cumulative system effectiveness for the delivery of ITN through ANC stratified for health facility level 4 and 2/3 combined. Intermediate steps are as follows: step 1 attend ANC for first visit; step 2 ITN are in stock; step 3 an ITN is offered to the women; step 4 the women accepts and takes the ITN
Design effect and intra-cluster correlation for each intermediate step for the delivery of ITN and IPTp
| Delivery steps | Level 4 | Level 3 and 2 | Overall | |||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| % Pregnant women | % Range | DE | ICC | % Pregnant women | % Range | DE | ICC | % Pregnant women | % Range | DE | ICC | |
| ITN eligible: attend ANC first visit | 100.0 | 100 | 100 | |||||||||
| ITN in stock | 90.9 | (84.9–100.0) | 3.1 | 0.023 | 100 | 94.8 | (84.9–100.0) | 5.1 | 0.044 | |||
| Offered an ITN | 63.4 | (55.6–74.2) | 0.7 | −0.003 | 68.6 | (35.3–100.0) | 9.1 | 0.087 | 66.0 | (35.3–100.0) | 4.4 | 0.037 |
| IPTp eligiblea | 100.0 | 100 | 100 | |||||||||
| SP in stock | 100.0 | 100 | 100 | |||||||||
| Seen at ANC consultation | 100.0 | 100.0 | 99.7 | (98.6–100.0) | 0.7 | −0.003 | 99.9 | (98.5–100.0) | 0.9 | -0.001 | ||
| Being given SP during visit | 68.6 | (61.5–73.2) | 2.2 | 0.013 | 80.3 | (60.7–95.7) | 6.8 | 0.062 | 74.0 | (60.7–95.7) | 4.6 | 0.039 |
| Being given three tabs SP during visit | 99.0 | (98.2–100.0) | 0.9 | −0.001 | 94.1 | (76.5–100.0) | 5.1 | 0.044 | 96.5 | (46.4–95.7) | 4.9 | 0.042 |
| SP by DOT | 64.6 | (0.0–86.9) | 38.0 | 0.398 | 70.1 | (24.1–100.0) | 34.2 | 0.357 | 67.3 | (24.1–100.0) | 29.0 | 0.301 |
| Has SP on exit | 36.7 | (11.3–96.6) | 26.0 | 0.269 | 27.1 | (0–80.0) | 28.7 | 0.298 | 31.5 | (0–96.6) | 22.3 | 0.229 |
| Knows to take three tablets SP | 92.1 | (85.7–100.0) | 1.0 | 0.000 | 96.4 | (87.5–100.0 | 2.7 | 0.018 | 94.2 | (85.7–100.0) | 1.7 | 0.008 |
| Knows to take three tablets SP or took SP as DOT | 92.1 | (86.2–93.8) | 0.6 | −0.004 | 97.1 | (70.0–100.0) | 6.4 | 0.058 | 94.8 | (70.0–100.0) | 2.9 | 0.020 |
aIPTp eligibility according to Kenya national guidelines was women not taking cotrimoxazole (or being HIV positive as a proxy for cotrimoxazole use), having felt the baby move (i.e. past quickening) or being 16 weeks gestation or over
ANC antenatal care, DE design effect, DOT directly observed therapy, ICC intra-class correlation, IPTp intermittent preventive treatment, ITN insecticide-treated net, SP sulfadoxine–pyrimethamine